Sensius

Thermotherapy by Sensius will change the way we treat cancer. Why is this so important? We know cancer to be a terrible disease. Treatments are either very expensive or toxic. A patient may survive the tumor, but will he survive the treatment? Thus change is essential! 

Thermotherapy by Sensius changes the way we treat cancer. We create a new balance between survivorship and quality of life because we improve both.

It has been well proven in many phase III studies that heating the tumor to maximum fever levels triggers the natural responses of the body to fight the tumor cells and as we stay within the fever range, we do not induce any negative side effects or toxicity.

We use 20 microwave antennas around the tumor to focus the heat to the tumor. Our patented technology uses AI software to protect any nearby healthy tissue. We fully aligns with the radiotherapy workflow to make adoption in clinics easy. Our modular approach enables treatment of many tumor types in the body to make it economically attractive for clinics.

Our launching product is head and neck cancer: a retrospective study treating recurrent tumors with our clinical prototype demonstrated a significant improvement in complete response, even compared to earlier studies where heat was used to sensitize the tumor. 

Our business model is predominantly recurring revenues through our annual services and pay-per-patient software. We sell the hardware at attractive entry prices, but equipment as a service is also possible based on our asset-financing facilities.

Sensius will be come the 4th pillar in cancer treatment. It is beneficial for patients, it is profitable for clinics and it reduces the economic burden of cancer. Thermotherapy can be used on many tumor types. Our global addressable market is above 12 million euro.

Our current accomplishments are a patented and MDR approved clinical prototypes on which already 70 patients are treated with a new study underway. 20 Clinics in W-Europe, the UK and the USA are engaged to start a clinical confirmation study in 2027. 

Sensius is an EIC Accelerator supported company. Last year we were awarded with 4 research grants. 

In Sensius, highly reputed researchers have joined forces with seasoned entrepreneurs. You will find our knowledge, experience and commitment to be remarkable. We are reliable to our clients, suppliers and investors. And most of all, we are respectful to cancer patients and the people who care for them.

This year we closed our Series A funding round. We want to expand through direct sales in the USA and the launch of our solution for breast cancer.  In 2026 we want to raise 10-12 million for this purpose.